Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Steve Pakola, MD
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.
In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.
Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.
